Skip to main content
Figure 3 | BMC Psychiatry

Figure 3

From: Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials

Figure 3

Kaplan Meier (KM) Analysis of olanzapine versus ziprasidone for days to loss of response, where loss of response was defined as a ≥ 20% worsening of PANSS 1–7 Total score and a CGI-S score ≥ 3 in patients who had a ≥ 20% improvement over baseline PANSS 1–7 Total score at Week 8. Olanzapine-treated patients remained in response for significantly longer than patients treated with ziprasidone (p < .008).

Back to article page